Find Clinical Trial

Home » Find Clinical Trials » Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 years. A randomised, double-blind, multicentre, placebo controlled, phase II/III dose-finding study with a PK/PD characterisation and a 1 year efficacy/safety evaluation.

Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 years. A randomised, double-blind, multicentre, placebo controlled, phase II/III dose-finding study with a PK/PD characterisation and a 1 year efficacy/safety evaluation.

← Back

Study Phase	Phase 2-3

Therapeutic Area	Cardiovascular Diseases

Indication	Heart failure

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	IVABRADINE, S016257

Active Substance Code	S016257

Protocol Code	CL2-16257-090

EudraCT Code	2011-001292-39

ISRCTN Code	ISRCTN60567801

Documents and links

Results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.